LyphoMed Inc said it is forminga new division, called IPHARM, to develop a full line ofgeneric and proprietary ophthalmic pharmaceuticals.    Lyphomed said in its initial phase the division willproduce products exclusively for the 200 mln dlr hospital useonly market.    The company said that in its next phase IPHARM will extendits market to include both hospital and non-hospital customerswhich it estimates to be valued at 800 mln dlrs to 1 billiondlrs in total.    Ultimately, Lyphomed said IPHARM will concentrate ondeveloping new proprietary ophthalmic dosage forms.    Lyphomed said the division has already submittedAbbreviated New Drug Applications to the Food and DrugAdministration and will submit several more within the next sixmonths.    Lyphomed said the division will operate out of its MelrosePark manufacturing facility and will be headed by RameshAcharya, Lyphomed vice president and general manager. Reuter&#3;